Danish Galecto has completed the acquisition of US biotechnology company Damora Therapeutics, which is developing antibody treatments for blood cancers caused by mutated calreticulin (mutCALR). At the same time, an oversubscribed capital raising of USD 285 million led by Fairmount and several large institutional investors is being carried out, securing financing until 2029. The acquisition adds Galecto to a portfolio of drug candidates for myeloproliferative neoplasms (MPN), with the lead candidate DMR-001 expected to enter the clinic in 2026.